Drug Search Results
More Filters [+]

ACTR-087

Alternative Names: actr-087, actr087, actr 087
Latest Update: 2020-03-31
Latest Update Note: Clinical Trial Update

Product Description

Cogent Biosciences is developing ACTR-087 as a treatment for multiple myeloma and b-cell lymphoma. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03266692, https://clinicaltrials.gov/ct2/show/NCT02776813)

Mechanisms of Action: 4-1BB Antagonist,CD3 Antagonist

Novel Mechanism: Yes

Modality: Bispecific Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cogent Biosciences
Company Location: CAMBRIDGE MA 02140
Company CEO: Andrew Robbins
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ACTR-087

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Multiple Myeloma|Lymphoma, B-Cell

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

UT-201501

P1

Completed

Lymphoma, B-Cell

2020-02-12

29%

ATTCK-17-01

P1

Terminated

Multiple Myeloma

2019-10-01

29%

ATTCK-17-01

P1

Terminated

Multiple Myeloma

2019-10-01

29%

Recent News Events